公开(公告)号：US12186387B2

公开(公告)日：2025-01-07

申请号：US18071499

申请日：2022-11-29

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Asaf Poran ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin

IPC: A61K39/215 ,  A61K9/127 ,  A61K39/145 ,  A61K45/06 ,  A61K47/26 ,  C12N15/86 ,  A61K39/00

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20240383947A1

公开(公告)日：2024-11-21

申请号：US18287608

申请日：2022-04-20

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alexander Muik

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/215 ,  A61K39/295 ,  A61P37/04

Abstract: This disclosure relates to the field of preventing or treating virus infection, in particular, the disclosure relates to agents for vaccination against virus infection and inducing effective virus antigen-specific immune responses such as antibody and/or T cell responses and methods for generating and using such agents. Administration of agents such as RNA disclosed herein to a subject can protect the subject against virus infection. Specifically, the present disclosure relates to amino acid sequences comprising at least a portion of a virus protein having amino acid modifications found in other variants of the virus protein. Administration of RNA encoding one or more of the amino acid sequences may provide protection against diverse virus variants. Methods and agents described herein are, in particular, useful for the prevention or treatment of coronavirus infection such as SARS-CoV-2 infection.

公开(公告)号：US20240339174A1

公开(公告)日：2024-10-10

申请号：US18289425

申请日：2022-05-04

Applicant: BioNTech SE ,  InstaDeep Ltd.

Inventor： Alexander Muik ,  Asaf Poran ,  Yunpeng Liu ,  Ugur Sahin ,  Karim Beguir ,  Marcin Skwark ,  Thomas Pierrot ,  Yunguan Fu

IPC: G16B20/20 ,  C07K14/005 ,  G16B15/30 ,  G16B40/20

CPC classification number: G16B20/20 ,  C07K14/005 ,  G16B15/30 ,  G16B40/20 ,  C12N2770/20022

Abstract: The present disclosure provides technologies for identifying, characterizing, and/or monitoring sequences of a variant of a reference infectious agent (e.g., but not limited to viral variants, for example in some embodiments SARS-CoV-2 variants) for transmissibility factors and/or immune escape potential, and/or for detecting and/or monitoring variants in environmental or biological samples, and/or for designing, preparing, and/or administering vaccines for such variants.

公开(公告)号：US20240042011A1

公开(公告)日：2024-02-08

申请号：US18186914

申请日：2023-03-20

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Asaf Poran ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin

IPC: A61K39/215 ,  A61K39/145 ,  A61K9/127 ,  A61K47/26 ,  C12N15/86

CPC classification number: A61K39/215 ,  A61K39/145 ,  A61K2039/545 ,  A61K47/26 ,  C12N15/86 ,  A61K9/1272

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20240366751A1

公开(公告)日：2024-11-07

申请号：US18526938

申请日：2023-12-01

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Asaf Poran ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin ,  Kayvon Modjarrad

IPC: A61K39/215 ,  A61K39/00 ,  C07K14/005

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.

公开(公告)号：US12133899B2

公开(公告)日：2024-11-05

申请号：US17988742

申请日：2022-11-16

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20240002127A1

公开(公告)日：2024-01-04

申请号：US17920569

申请日：2021-04-16

Applicant: Pfizer Inc. ,  BioNTech SE

Inventor： Marjoh Nauta ,  Dirk Jozef Peeters ,  Tom Frank Steven Van Doorslaer ,  Advait Vijay Badkar ,  Ramin Darvari ,  Nicholas William Warne ,  James Jean ,  Danny Pierre G. Hendrikse ,  Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: B65D81/127 ,  A61K39/215 ,  B65D77/04 ,  B65D81/38

CPC classification number: B65D81/127 ,  A61K39/215 ,  A61K2039/55555 ,  B65D81/3813 ,  B65D77/0413

Abstract: The present disclosure relates to the fields of packaging, transportation, and storage of temperature-sensitive materials, such as biological and/or pharmaceutical products. Various aspects of such packaging, transportation, and storage are provided herein for ultra-low temperature materials useful for the treatment and/or prevention of disease. The present disclosure also provides packaging materials, methods of transportation, and methods of storage for maintaining biological and/or pharmaceutical materials at ultra-low temperatures in order to maintain the integrity of the materials. The present disclosure further relates to the field of RNA to prevent or treat coronavirus infection.

公开(公告)号：US20230201817A1

公开(公告)日：2023-06-29

申请号：US18085206

申请日：2022-12-20

Applicant: BioNTech Delivery Technologies GmbH ,  BioNTech SE

Inventor： Christian Reinsch ,  David Estapé Izquierdo ,  Sierk Poetting ,  Ugur Sahin ,  Alexander Muik ,  Asaf Poran ,  Martin Lang ,  Oliver Hennig ,  Karsten Pietron-Kattmann ,  Manfred Brunen ,  Rainer Kröner ,  Mario Büttner ,  Sven Stegmann ,  Kristin Hoffmann

IPC: B01L1/00 ,  G16B30/00 ,  G16B50/30 ,  G16B20/20 ,  A61K39/215 ,  B01F25/25 ,  B01D61/14

CPC classification number: B01L1/52 ,  A61K39/215 ,  B01D61/145 ,  B01D61/147 ,  B01D61/149 ,  B01F25/25 ,  G16B20/20 ,  G16B30/00 ,  G16B50/30 ,  A61K2039/53

Abstract: A portable system for producing a formulation comprising lipid nanoparticle (LNP)-encapsulated RNA includes: a first sub-system comprising multiple drug substance formulation modules, the first sub-system comprising: a transcription module for forming an RNA solution via in vitro transcription; and a second sub-system operatively downstream of the first sub-system comprising multiple drug product formation modules, the second sub-system comprising: an LNP formulation module for producing a first RNA-LNP preparation from the RNA solution, wherein each of the transcription module and the LNP formulation module is contained within a separate standard shipping container.

公开(公告)号：US20240355417A1

公开(公告)日：2024-10-24

申请号：US18618412

申请日：2024-03-27

Applicant: BioNTech SE ,  InstaDeep Ltd

Inventor： Alexander Muik ,  Ugur Sahin ,  Asaf Poran ,  Alexandra Walls ,  Yunguan Fu ,  Rafal Okuniewski ,  Nicolas Winfried Pfeuffer

IPC: G16B20/50 ,  G16B40/20 ,  G16B45/00 ,  G16B50/30 ,  G16H50/80

CPC classification number: G16B20/50 ,  G16B40/20 ,  G16B45/00 ,  G16B50/30 ,  G16H50/80

Abstract: The present disclosure, among other things, provides technologies for identifying, characterizing, and/or monitoring variant sequences of a particular reference infections agent. Among other things, systems, methods, and architectures described herein provide visualization and decision support tools that can, e.g., facilitate decision making processes by local authorities and improve pandemic response in terms of, e.g., resource allocation, policy making, and speed tailored vaccine development. The present disclosure also provides tools for analyzing circulating variants to predict mutations likely to increase immune evasion of infectious agents.

公开(公告)号：US20240321387A1

公开(公告)日：2024-09-26

申请号：US18289424

申请日：2022-05-04

Applicant: BioNTech SE ,  InstaDeep Ltd

Inventor： Alexander Muik ,  Asaf Poran ,  Yunpeng Liu ,  Ugur Sahin ,  Karim Beguir ,  Marcin Skwark ,  Thomas Pierrot ,  Yunguan Fu

IPC: G16B15/30 ,  G06N3/045 ,  G06N3/08 ,  G06N5/01 ,  G06N20/00 ,  G16B40/20

CPC classification number: G16B15/30 ,  G06N3/045 ,  G06N3/08 ,  G06N5/01 ,  G06N20/00 ,  G16B40/20

Abstract: A method is provided for identifying a number of variants of concern of a reference disease associated immunogen. The method uses a language model to perform inference on data representing each of a plurality of variants and data representing the reference immunogen. For each of the plurality of variants and the reference immunogen, a characteristic vector is derived from an output feature map of a hidden layer of the language model. For each of the plurality of variants, a measure of distance is generated for the variant that includes calculating a measure of distance between the characteristic vector of the variant and the characteristic vector of the reference immunogen. A semantic change score is calculated for each variant based on the generated measure of distance for that variant. A variant of the reference immunogen is selected based, at least in part, on the generated the semantic change scores.